As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

 
• By David Wild

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.  

Waiting For Market Uptake Of Competing Gene-Based Therapies • Source: Shutterstock

More from Market Access

More from In Vivo